H.H. Hansen
Impact in
- Toxicology top 5%
- Bioactive Compounds and Antitumor Agents
- Oncology top 10%
- Lung Cancer Research Studies
- Neutropenia and Cancer Infections
- Cancer Treatment and Pharmacology
Papers in
- Co-authors
- Oleg S. Selawry (3 shared papers)Patrick J. Creaven (3 shared papers)Franco M. Muggia (3 shared papers)Maurice Cohen (2 shared papers)Svend Boe (2 shared papers)J F Holland (1 shared paper)E Bork (2 shared papers)F. Stelzner (4 shared papers)
- Journals
- Langenbeck s Archives of Surgery (10 papers)European Journal of Cancer (4 papers)British Journal of Cancer (2 papers)Cancer Chemotherapy and Pharmacology (2 papers)Lung Cancer (2 papers)
- Partner nations
- GermanyDenmarkUnited States
In The Last Decade
H.H. Hansen
44 papers receiving 683 citations
Peers
Comparison fields: 5 of 80
- Toxicology 50
- Oncology 330
- Surgery 215
- Molecular Biology 318
- Rheumatology 66
Countries citing papers authored by H.H. Hansen
This map shows the geographic impact of H.H. Hansen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H.H. Hansen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H.H. Hansen more than expected).
Fields of papers citing papers by H.H. Hansen
This network shows the impact of papers produced by H.H. Hansen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H.H. Hansen. The network helps show where H.H. Hansen may publish in the future.
Co-authors
The 25 scholars most cited alongside H.H. Hansen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 46 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. | 1972 | 275 |
| 2 | 1971 | 56 | |
| 3 | Intestinal obstruction in patients with advanced carcinoma of the ovaries treated with combination chemotherapy. | 1989 | 38 |
| 4 | 1987 | 38 | |
| 5 | Phase I clinical trial of isophosphamide (NSC-109724). | 1975 | 37 |
| 6 | 1968 | 30 | |
| 7 | 1986 | 27 | |
| 8 | 1973 | 27 | |
| 9 | 1988 | 23 | |
| 10 | 1989 | 22 | |
| 11 | 1989 | 17 | |
| 12 | 1982 | 16 | |
| 13 | 1976 | 15 | |
| 14 | 1982 | 13 | |
| 15 | 1987 | 12 | |
| 16 | 1995 | 11 | |
| 17 | 1975 | 9 | |
| 18 | 1971 | 8 | |
| 19 | 1984 | 7 | |
| 20 | 1975 | 7 |
About H.H. Hansen
H.H. Hansen is a scholar working on Surgery, Oncology, Pulmonary and Respiratory Medicine, Epidemiology and Molecular Biology, having authored 46 papers that have together received 760 indexed citations. Recurring topics across this work include Lung Cancer Research Studies (7 papers), Lung Cancer Treatments and Mutations (5 papers), Cancer therapeutics and mechanisms (4 papers), Anorectal Disease Treatments and Outcomes (4 papers), Neuroendocrine Tumor Research Advances (4 papers), Diverticular Disease and Complications (3 papers), Knee injuries and reconstruction techniques (3 papers) and Colorectal Cancer Surgical Treatments (3 papers). The work is most often cited by research in Toxicology (50 citations), Oncology (330 citations), Surgery (215 citations), Molecular Biology (318 citations) and Rheumatology (66 citations). H.H. Hansen has collaborated with scholars based in Germany, Denmark and United States. Frequent co-authors include Oleg S. Selawry, Patrick J. Creaven, Franco M. Muggia, Maurice Cohen, Svend Boe, J F Holland, E Bork, F. Stelzner, M. Clerici and Larry M. Allen. Their work appears in journals such as Langenbeck s Archives of Surgery, European Journal of Cancer, British Journal of Cancer, Cancer Chemotherapy and Pharmacology and Lung Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.